Antiviral Activity of Anthranilamide Peptidomimetics against Herpes Simplex Virus 1 and a Coronavirus.

Umme Laila Urmi, Samuel Attard, Ajay Kumar Vijay, Mark D P Willcox, Naresh Kumar, Salequl Islam, Rajesh Kuppusamy

Abstract read

In one paragraph

Article in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it

0cells of the map it votes in

5citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

Polymer- and peptide-based antiviral surface coatings: progress, mechanistic gaps, and future directions.Applied and environmental microbiology · 2026
Review
Antimicrobial activity of a short guanidine mimic immobilised on contact lenses.Journal of materials science. Materials in medicine · 2026
Article
Membrane-Targeting Antivirals.International journal of molecular sciences · 2025
Review
Harnessing Non-Antibiotic Strategies to Counter Multidrug-Resistant Clinical Pathogens with Special Reference to Antimicrobial Peptides and Their Coatings.Antibiotics (Basel, Switzerland) · 2025
Review
Exploring the Efficacy of Peptides and Mimics against Influenza A Virus, Adenovirus, and Murine Norovirus.International journal of molecular sciences · 2024
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Umme Laila UrmiSchool of Optometry and Vision Science, University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0003-1327-1638

Samuel AttardSchool of Chemistry, University of New South Wales, Sydney, NSW 2052, Australia.

Ajay Kumar VijaySchool of Optometry and Vision Science, University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0002-8248-6379

Mark D P WillcoxSchool of Optometry and Vision Science, University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0003-3842-7563

Naresh KumarSchool of Chemistry, University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0002-0951-9621

Salequl IslamSchool of Optometry and Vision Science, University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0001-6131-4132

Rajesh KuppusamySchool of Optometry and Vision Science, University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0001-9844-5064

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of potent antiviral agents is of utmost importance to combat the global burden of viral infections. Traditional antiviral drug development involves targeting specific viral proteins, which may lead to the emergence of resistant strains. To explore alternative strategies, we investigated the antiviral potential of antimicrobial peptidomimetic compounds. In this study, we evaluated the antiviral potential of 17 short anthranilamide-based peptidomimetic compounds against two viruses: Murine hepatitis virus 1 (MHV-1) which is a surrogate of human coronaviruses and herpes simplex virus 1 (HSV-1). The half-maximal inhibitory concentration (IC

Indexed as

antiviral compoundsenvelope disruptionHSV-1MHV-1peptidomimetics

Identifiers

PMID37760732

DOI10.3390/antibiotics12091436

PMCPMC10525570

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.